PE20060739A1 - FORMAS CRISTALINAS DE 3-(1-HIDROXI-1-METIL-ETIL)-1-(4-METOXI-FENIL)-6-[4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-1,4,5,6-TETRAHIDRO-PIRAZOLO[3,4-c]PIRIDIN-7-ONA COMO INHIBIDORES DEL FACTOR Xa - Google Patents
FORMAS CRISTALINAS DE 3-(1-HIDROXI-1-METIL-ETIL)-1-(4-METOXI-FENIL)-6-[4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-1,4,5,6-TETRAHIDRO-PIRAZOLO[3,4-c]PIRIDIN-7-ONA COMO INHIBIDORES DEL FACTOR XaInfo
- Publication number
- PE20060739A1 PE20060739A1 PE2005001450A PE2005001450A PE20060739A1 PE 20060739 A1 PE20060739 A1 PE 20060739A1 PE 2005001450 A PE2005001450 A PE 2005001450A PE 2005001450 A PE2005001450 A PE 2005001450A PE 20060739 A1 PE20060739 A1 PE 20060739A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- phenyl
- crystalline forms
- ona
- pyrazolo
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 title abstract 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical class COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63638704P | 2004-12-15 | 2004-12-15 | |
| US73798505P | 2005-11-18 | 2005-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060739A1 true PE20060739A1 (es) | 2006-08-16 |
Family
ID=36384503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001450A PE20060739A1 (es) | 2004-12-15 | 2005-12-14 | FORMAS CRISTALINAS DE 3-(1-HIDROXI-1-METIL-ETIL)-1-(4-METOXI-FENIL)-6-[4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-1,4,5,6-TETRAHIDRO-PIRAZOLO[3,4-c]PIRIDIN-7-ONA COMO INHIBIDORES DEL FACTOR Xa |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7371864B2 (enExample) |
| EP (1) | EP1828187A2 (enExample) |
| JP (1) | JP2008524228A (enExample) |
| KR (1) | KR20070087606A (enExample) |
| AR (1) | AR053990A1 (enExample) |
| AU (1) | AU2005317158A1 (enExample) |
| BR (1) | BRPI0519331A2 (enExample) |
| CA (1) | CA2589886A1 (enExample) |
| IL (1) | IL183825A0 (enExample) |
| MX (1) | MX2007006919A (enExample) |
| NO (1) | NO20072666L (enExample) |
| PE (1) | PE20060739A1 (enExample) |
| RU (1) | RU2007126770A (enExample) |
| TW (1) | TW200634011A (enExample) |
| WO (1) | WO2006065853A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2636757B1 (en) | 2008-05-27 | 2016-11-23 | Dako Denmark A/S | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers |
| US9303287B2 (en) | 2009-02-26 | 2016-04-05 | Dako Denmark A/S | Compositions and methods for RNA hybridization applications |
| WO2013046033A1 (en) | 2011-09-30 | 2013-04-04 | Dako Denmark A/S | Hybridization compositions and methods using formamide |
| EP3252173A1 (en) | 2011-10-21 | 2017-12-06 | Dako Denmark A/S | Hybridization compositions and methods |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI331526B (en) * | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| GEP20074098B (en) * | 2001-09-21 | 2007-05-10 | Bristol Myers Squibb Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| US20060069085A1 (en) * | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060069260A1 (en) * | 2004-09-28 | 2006-03-30 | Huiping Zhang | Preparation of N-aryl pyridones |
| US7388096B2 (en) | 2004-09-28 | 2008-06-17 | Bristol-Myers Squibb Company | Crystalline forms of a factor Xa inhibitor |
| US7304157B2 (en) * | 2004-09-28 | 2007-12-04 | Bristol-Myers Squibb Company | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
-
2005
- 2005-12-14 RU RU2007126770/04A patent/RU2007126770A/ru not_active Application Discontinuation
- 2005-12-14 WO PCT/US2005/045158 patent/WO2006065853A2/en not_active Ceased
- 2005-12-14 BR BRPI0519331-1A patent/BRPI0519331A2/pt not_active IP Right Cessation
- 2005-12-14 MX MX2007006919A patent/MX2007006919A/es active IP Right Grant
- 2005-12-14 EP EP05853961A patent/EP1828187A2/en not_active Withdrawn
- 2005-12-14 TW TW094144289A patent/TW200634011A/zh unknown
- 2005-12-14 CA CA002589886A patent/CA2589886A1/en not_active Abandoned
- 2005-12-14 JP JP2007546841A patent/JP2008524228A/ja active Pending
- 2005-12-14 US US11/302,692 patent/US7371864B2/en active Active
- 2005-12-14 KR KR1020077013364A patent/KR20070087606A/ko not_active Withdrawn
- 2005-12-14 AU AU2005317158A patent/AU2005317158A1/en not_active Abandoned
- 2005-12-14 PE PE2005001450A patent/PE20060739A1/es not_active Application Discontinuation
- 2005-12-14 AR ARP050105253A patent/AR053990A1/es unknown
-
2007
- 2007-05-25 NO NO20072666A patent/NO20072666L/no unknown
- 2007-06-10 IL IL183825A patent/IL183825A0/en unknown
-
2008
- 2008-04-09 US US12/099,906 patent/US20080188517A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0519331A2 (pt) | 2009-01-20 |
| US7371864B2 (en) | 2008-05-13 |
| JP2008524228A (ja) | 2008-07-10 |
| TW200634011A (en) | 2006-10-01 |
| US20060148846A1 (en) | 2006-07-06 |
| WO2006065853A3 (en) | 2006-08-24 |
| NO20072666L (no) | 2007-09-07 |
| KR20070087606A (ko) | 2007-08-28 |
| AR053990A1 (es) | 2007-05-30 |
| MX2007006919A (es) | 2007-06-26 |
| WO2006065853A2 (en) | 2006-06-22 |
| CA2589886A1 (en) | 2006-06-22 |
| EP1828187A2 (en) | 2007-09-05 |
| AU2005317158A1 (en) | 2006-06-22 |
| RU2007126770A (ru) | 2009-01-27 |
| US20080188517A1 (en) | 2008-08-07 |
| IL183825A0 (en) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| PE20141197A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| SV2010003662A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081 | |
| EA201290757A1 (ru) | Бициклические соединения и их применение в качестве ингибиторов двойного действия c-src/jak | |
| WO2006014665A3 (en) | Arylpyrrolidine derivatives as nk-1/ssri antagonists | |
| NI201600166A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
| WO2007143434A3 (en) | Indazole and isoindole derivatives as glucokinase activating agents | |
| CY1123426T1 (el) | Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος | |
| UA115228C2 (uk) | Інгібітори протеїнкіназ (варіанти), їх застосування для лікування онкологічних захворювань та фармацевтична композиція на їх основі | |
| NO20076447L (no) | Bicykliske derivater som modulatorer av ionekanaler | |
| NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
| UA95940C2 (uk) | Азаіндоли як інгібітори кіназ януса | |
| EP3037421A3 (en) | Mlk inhibitors and methods of use | |
| NI201000079A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrófilos. | |
| MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
| ECSP056131A (es) | Compuestos de carbonilo | |
| MX2012008911A (es) | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona. | |
| ATE497961T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
| WO2007109251A3 (en) | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | |
| NO20085135L (no) | Selektive inhibitorer av ROCK-proteinkinase og anvendelse derav | |
| EA200901484A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
| EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| DOP2009000285A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |